Targeting immunosuppression by Tregs with monoclonal antibodies against GARP

S Liénart, J Stockis, O Dedobbeleer, S Lucas - Oncoimmunology, 2016 - Taylor & Francis
S Liénart, J Stockis, O Dedobbeleer, S Lucas
Oncoimmunology, 2016Taylor & Francis
Reducing Treg function in cancer patients should augment antitumor immune responses.
We recently uncovered a mechanism of immunosuppression by human Tregs that implies
transmembrane protein GARP and production of active TGF-ß1. We obtained monoclonal
antibodies that block this process and could thus serve as a novel approach for cancer
immunotherapy.
Abstract
Reducing Treg function in cancer patients should augment antitumor immune responses. We recently uncovered a mechanism of immunosuppression by human Tregs that implies transmembrane protein GARP and production of active TGF-ß1. We obtained monoclonal antibodies that block this process and could thus serve as a novel approach for cancer immunotherapy.
Taylor & Francis Online